These inhibitors may be used, as we showedhere, as monotherapy, in combination with standard anthracycline therapy or with other drugs, suchas a recently identified PLK4 inhibitor, which show strong anti-tumor activity againstPten-deficient BC (Mason et al, 2014). Here, PLK4 is linked to breast cancer.